Startseite/Aktien/ALT

ALT

USD

Altimmune Inc. Common Stock

$4.110+0.190 (4.847%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$3.920

Hoch

$4.160

Tief

$3.775

Volumen

2.59M

Unternehmensfundamentaldaten

Marktkapitalisierung

428.8M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.84M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $2.9Aktuell $4.110Hoch $11.16

Ähnliche Nachrichten

3. Nov. 2025 · 12:30

GlobeNewswire

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

30. Okt. 2025 · 16:42

Reuters

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

30. Okt. 2025 · 11:30

GlobeNewswire

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,